• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Jade Biosciences, Inc. - Common Stock (NQ:JBIO)

    13.44 UNCHANGED
    Delayed Quote Updated: 4:00 PM EDT, Oct 14, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 0
    Open 13.44
    Bid (Size) 13.10 (100)
    Ask (Size) 13.90 (100)
    Prev. Close 13.44
    Today's Range 13.44 - 13.44
    52wk Range 8.360 - 28.00
    Shares Outstanding 28,985,019
    Dividend Yield 17.86%
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    Jade Biosciences Announces Preclinical Data Characterizing JADE301, a Potentially Best-in-Class, Half-Life-Extended Anti-IFN-β Monoclonal Antibody in Development for Dermatomyositis, at EADV 2026
    From Jade Biosciences
    Via GlobeNewswire
    News headline image
    Jade Biosciences to Participate in Upcoming Conferences
    From Jade Biosciences
    Via GlobeNewswire

    Performance

    52-Week Range 52.0% below 52-week high
    13.44
    8.3652W Low 28.0052W High
    1 Week 9.3% below 1-week high
    12.851W Low 14.811W High

    Jade Biosciences, Inc. - Common Stock (JBIO) traded between $8.36 and $28.00 over the past 52 weeks and last traded at $13.44, 52.0% below its 52-week high. Over the past week it ranged between $12.85 and $14.81.

    Past 12 Months
    -5.0%
    -26.1%
    -38.5%
    -30.2%
    -5.1%
    +46.9%
    1W -$0.71
    1M -$4.74
    3M -$8.42
    6M -$5.82
    YTD -$0.72
    1Y +$4.29

    JBIO was +46.9% over the past year, -30.2% over six months, -5.1% year to date, -5.0% in the last week.

    12 Months vs Market
    JBIO
    +46.9%
    DIA
    +11.4%
    SPY
    +16.2%
    QQQ
    +21.9%
    IWM
    +9.5%

    Over the past 12 months JBIO returned +46.9% versus DIA (Dow) +11.4%, SPY (S&P 500) +16.2%, QQQ (Nasdaq 100) +21.9% and IWM (Russell 2000) +9.5%.

    Volume & Liquidity
    1W
    1.3M
    1M
    1.0M
    3M
    896.5K
    6M
    963.5K
    YTD
    765.0K
    1Y
    660.3K

    JBIO's 3-month average daily volume is 896.5K.

    More News

    Read More
    News headline image
    Jade Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate Update
    From Jade Biosciences
    Via GlobeNewswire
    News headline image
    Jade Biosciences Announces Appointment of Mark Eisner, M.D., M.P.H., to Board of Directors
    From Jade Biosciences
    Via GlobeNewswire
    News headline image
    Jade Biosciences Announces Closing of Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
    From Jade Biosciences
    Via GlobeNewswire
    News headline image
    Jade Biosciences Announces Pricing of Public Offering of Common Stock
    From Jade Biosciences
    Via GlobeNewswire
    News headline image
    Jade Biosciences Announces Proposed Underwritten Public Offering
    From Jade Biosciences
    Via GlobeNewswire
    News headline image
    Jade Biosciences’ JADE101 Delivers Deep IgA Cuts, Clearing Path for Kidney Trials ↗
    Via MarketBeat
    News headline image
    Jade Biosciences Announces Positive Interim Phase 1 Results for JADE101 Demonstrating Potential Best-in-Class Profile and Every-12-Week Dosing in IgA Nephropathy
    From Jade Biosciences
    Via GlobeNewswire
    What's going on in today's after hours session ↗
    Via Chartmill
    News headline image
    Jade Biosciences to Host Conference Call and Webcast on June 1, 2026, at 8:00 a.m. ET to Discuss Interim Phase 1 Healthy Volunteer Results for JADE101, a Novel, Potentially Best-in-Class Anti-APRIL Monoclonal Antibody in Development for IgA Nephropathy
    From Jade Biosciences
    Via GlobeNewswire
    News headline image
    Jade Biosciences Announces First Participant Dosed in First-in-Human Phase 1 Clinical Trial of JADE201, a Novel Half-Life Extended Afucosylated Anti-BAFF Receptor Monoclonal Antibody
    From Jade Biosciences
    Via GlobeNewswire
    News headline image
    Jade Biosciences Announces First Participant Dosed in Phase 2 JUNIPER Clinical Trial of JADE101 in IgA Nephropathy
    From Jade Biosciences
    Via GlobeNewswire
    News headline image
    Why This Biotech Fund Added $7 Million to an Oncology Stock Up 120% ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Why This Biotech Fund Opened a $9 Million Position in a Newly Public Cancer Company ↗
    Via The Motley Fool
    Topics Initial Public Offering Regulatory Compliance
    News headline image
    Why This Biotech Fund Increased Its Oruka Therapeutics Stake Amid a Staggering 500% Rally ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Jade Biosciences Reports First Quarter 2026 Financial Results and Provides Corporate Update
    From Jade Biosciences
    Via GlobeNewswire
    News headline image
    Jade Biosciences Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
    From Jade Biosciences
    Via GlobeNewswire
    News headline image
    Jade Biosciences Appoints Edward R. Conner, M.D., as Chief Medical Officer
    From Jade Biosciences
    Via GlobeNewswire
    News headline image
    Jade Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
    From Jade Biosciences
    Via GlobeNewswire
    News headline image
    Jade Biosciences to Participate in Upcoming Conferences
    From Jade Biosciences
    Via GlobeNewswire
    News headline image
    Jade Biosciences Outlines Key 2026 Objectives and Strategy to Advance Pipeline of Potentially Best-in-Class Monoclonal Antibodies Across Multiple Autoimmune Diseases Ahead of the 44th Annual J.P. Morgan Healthcare Conference
    From Jade Biosciences
    Via GlobeNewswire
    News headline image
    Jade Biosciences Announces $45 Million Private Placement
    From Jade Biosciences
    Via GlobeNewswire
    News headline image
    Jazz Pharmaceuticals, Sigma Lithium, Zymeworks And Other Big Stocks Moving Higher On Monday ↗
    Via Benzinga
    News headline image
    Jade Biosciences Reports Third Quarter 2025 Financial Results and Provides Corporate Update
    From Jade Biosciences
    Via GlobeNewswire

    Frequently Asked Questions

    Is Jade Biosciences, Inc. - Common Stock publicly traded?
    Yes, Jade Biosciences, Inc. - Common Stock is publicly traded.
    What exchange does Jade Biosciences, Inc. - Common Stock trade on?
    Jade Biosciences, Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Jade Biosciences, Inc. - Common Stock?
    The ticker symbol for Jade Biosciences, Inc. - Common Stock is JBIO on the Nasdaq Stock Market
    What is the current price of Jade Biosciences, Inc. - Common Stock?
    The current price of Jade Biosciences, Inc. - Common Stock is 13.44
    When was Jade Biosciences, Inc. - Common Stock last traded?
    The last trade of Jade Biosciences, Inc. - Common Stock was at 10/14/26 04:00 PM ET
    What is the market capitalization of Jade Biosciences, Inc. - Common Stock?
    The market capitalization of Jade Biosciences, Inc. - Common Stock is 389.56M
    How many shares of Jade Biosciences, Inc. - Common Stock are outstanding?
    Jade Biosciences, Inc. - Common Stock has 390M shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.